#BEGIN_DRUGCARD DB00592

# AHFS_Codes:
08:08.00
92:02.00*

# ATC_Codes:
P02CB01
R03DA09

# Absorption:
Rapidly absorbed from the gastrointestinal tract

# Biotransformation:
About 25% is metabolized in the liver. Piperazine is nitrosated to form N -mononitrosopiperazine (MNPz) in gastric juice, which is then metabolized to N-nitroso-3-hydroxypyrrolidine (NHPYR).

# Brand_Mixtures:
Canoids Cap (Aloin + Areca Catechu + Arecoline HBr + Benzocaine + Piperazine Citrate + Santonin)
Dyrex T F (Phenothiazine + Piperazine + Trichlorfon)
Feloids Tab (Aloin + Areca Catechu + Arecoline HBr + Benzocaine + Piperazine Citrate + Santonin)
Multi Wormer for Cats (Dichlorophene + Piperazine (Piperazine Citrate))
Multi Wormer for Dogs (Dichlorophene + Piperazine (Piperazine Citrate))
Ripercol Horse Wormer (Piperazine (Piperazine Hydrochloride) + Tetramisole HCl)

# Brand_Names:
Anatensol
Antepar
Antiren
Asca-Trol No. 3
Dapotum
Dispermine
Eraverm
Lumbrical
Moditen
Multifuge
Omca
Pacinol
Permitil
Piperazidine
Pipersol
Tasnon
Tensofin
Upixon
Uvilon
Vermex
Vermidol
Vermizine
Worm-A-Ton
Worm-away
Wurmirazin

# CAS_Registry_Number:
110-85-0

# ChEBI_ID:
28568

# Chemical_Formula:
C4H10N2

# Chemical_IUPAC_Name:
piperazine

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
97128

# Description:
Piperazine is an organic compound that consists of a six-membered ring containing two opposing nitrogen atoms. Piperazine exists as small alkaline deliquescent crystals with a saline taste.

Piperazine was introduced to medicine as a solvent for uric acid. When taken into the body the drug is partly oxidized and partly eliminated unchanged. Outside the body, piperazine has a remarkable power to dissolve uric acid and producing a soluble urate, but in clinical experience it has not proved equally successful.

Piperazine was first introduced as an anthelmintic in 1953. A large number of piperazine compounds have anthelmintic action. Their mode of action is generally by paralysing parasites, which allows the host body to easily remove or expel the invading organism.

# Dosage_Forms:
Liquid	Oral
Solution / drops	Oral
Syrup	Oral

# Drug_Category:
Anthelmintics
Antinematodal Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-1.50

# Experimental_Logs:
1.07

# Experimental_Water_Solubility:
1E+006 mg/L (at 25 °C)

# Food_Interactions:
Take without regard to meals.

# GenBank_ID:
Not Available

# Generic_Name:
Piperazine

# HET_ID:
169

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C4H10N2/c1-2-6-4-3-5-1/h5-6H,1-4H2

# InChI_Key:
InChIKey=GLUUGHFHXGJENI-UHFFFAOYSA-N

# Indication:
Used as alternative treatment for ascariasis caused by <i>Ascaris lumbricoides</i> (roundworm) and enterobiasis (oxyuriasis) caused by <i>Enterobius vermicularis</i> (pinworm). It is also used to treat partial intestinal obstruction by the common roundworm, a condition primarily occurring in children.

# KEGG_Compound_ID:
C07973

# KEGG_Drug_ID:
D00807

# LIMS_Drug_ID:
592

# Mechanism_Of_Action:
Piperazine is a GABA receptor agonist. Piperzine binds directly and selectively to muscle membrane GABA receptors, presumably causing hyperpolarization of nerve endings, resulting in flaccid paralysis of the worm. While the worm is paralyzed, it is dislodged from the intestinal lumen and expelled live from the body by normal intestinal peristalsis.

# Melting_Point:
106 °C

# Molecular_Weight_Avg:
86.1356

# Molecular_Weight_Mono:
86.08439833

# Organisms_Affected:
Parasitic nematodes and other roundworms

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA450977

# Pharmacology:
Piperazine is an anthelminthic especially useful in the treatment of partial intestinal obstruction caused by Ascaris worms, which is a condition primarily seen in children. Piperazine hydrate and piperazine citrate are the main anthelminthic piperazines.

# Predicted_LogP_Hydrophobicity:
-1.2

# Predicted_LogS:
0.63

# Predicted_Water_Solubility:
3.71e+02 g/l

# Primary_Accession_No:
DB00592

# Protein_Binding:
60-70%

# PubChem_Compound_ID:
4837

# PubChem_Substance_ID:
46507642

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00225

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
C1CNCCN1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Diethylenediamine
Diethyleneimine
Hexahydropyrazine
Piperazin
Piperazin [Germany]
Piperazine hexahydrate
Piperazine hydrate
fluphenazine dihydrochloride

# Synthesis_Reference:
Not Available

# Toxicity:
LD<sub>50</sub> = 5 g/kg (Human, oral). Symptoms of overdose include muscle fatigue, seizures, and difficulty breathing.

# Update_Date:
2013-02-08 16:19:28 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Piperazine

# pKa_Isoelectric_Point:
9.73

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP2D6

# Phase_1_Metabolizing_Enzyme_1_ID:
4119

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 2D6

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 2D6
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
FAFLVSPSPYELCAVPR

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P10635

# Drug_Target_1_Cellular_Location:
Membrane

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
11156579	Maskell PD, Wafford KA, Bermudez I: Effects of gamma-HCH and delta-HCH on human recombinant GABA(A) receptors: dependence on GABA(A) receptor subunit combination. Br J Pharmacol. 2001 Jan;132(1):205-12.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
GABRB3

# Drug_Target_1_GenBank_ID_Gene:
M82919

# Drug_Target_1_GenBank_ID_Protein:
182925

# Drug_Target_1_GeneCard_ID:
GABRB3

# Drug_Target_1_Gene_Name:
GABRB3

# Drug_Target_1_Gene_Sequence:
>1422 bp
ATGTGGGGCCTTGCGGGAGGAAGGCTTTTCGGCATCTTCTCGGCCCCGGTGCTGGTGGCT
GTGGTGTGCTGCGCCCAGAGTGTGAACGATCCCGGGAACATGTCCTTTGTGAAGGAGACG
GTGGACAAGCTGTTGAAAGGCTACGACATTCGCCTAAGACCCGACTTCGGGGGTCCCCCG
GTCTGCGTGGGGATGAACATCGACATCGCCAGCATCGACATGGTTTCCGAAGTCAACATG
GATTATACCTTAACCATGTATTTTCAACAATATTGGAGAGATAAAAGGCTCGCCTATTCT
GGGATCCCTCTCAACCTCACGCTTGACAATCGAGTGGCTGACCAGCTATGGGTGCCCGAC
ACATATTTCTTAAATGACAAAAAGTCATTTGTGCATGGAGTGACAGTGAAAAACCGCATG
ATCCGTCTTCACCCTGATGGGACAGTGCTGTATGGGCTCAGAATCACCACGACAGCAGCA
TGCATGATGGACCTCAGGAGATACCCCCTGGACGAGCAGAACTGCACTCTGGAAATTGAA
AGCTATGGCTACACCACGGATGACATTGAGTTTTACTGGCGAGGCGGGGACAAGGCTGTT
ACCGGAGTGGAAAGGATTGAGCTCCCGCAGTTCTCCATCGTGGAGCACCGTCTGGTCTCG
AGGAATGTTGTCTTCGCCACAGGTGCCTATCCTCGACTGTCACTGAGCTTTCGGTTGAAG
AGGAACATTGGATACTTCATTCTTCAGACTTATATGCCCTCTATACTGATAACGATTCTG
TCGTGGGTGTCCTTCTGGATCAATTATGATGCATCTGCTGCTAGAGTTGCCCTCGGGATC
ACAACTGTGCTGACAATGACAACCATCAACACCCACCTTCGGGAGACCTTGCCCAAAATC
CCCTATGTCAAAGCCATTGACATGTACCTTATGGGCTGCTTCGTCTTTGTGTTCCTGGCC
CTTCTGGAGTATGCCTTTGTCAACTACATTTTCTTTGGAAGAGGCCCTCAAAGGCAGAAG
AAGCTTGCAGAAAAGACAGCCAAGGCAAAGAATGACCGTTCAAAGAGCGAAAGCAACCGG
GTGGATGCTCATGGAAATATTCTGTTGACATCGCTGGAAGTTCACAATGAAATGAATGAG
GTCTCAGGCGGCATTGGCGATACCAGGAATTCAGCAATATCCTTTGACAACTCAGGAATC
CAGTACAGGAAACAGAGCATGCCTCGAGAAGGGCATGGGCGATTCCTGGGGGACAGAAGC
CTCCCGCACAAGAAGACCCATCTACGGAGGAGGTCTTCACAGCTCAAAATTAAAATACCT
GATCTAACCGATGTGAATGCCATAGACAGATGGTCCAGGATCGTGTTTCCATTCACTTTT
TCTCTTTTCAACTTAGTTTACTGGCTGTACTATGTTAACTGA

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
1664410	Wagstaff J, Chaillet JR, Lalande M: The GABAA receptor beta 3 subunit gene: characterization of a human cDNA from chromosome 15q11q13 and mapping to a region of conserved synteny on mouse chromosome 7. Genomics. 1991 Dec;11(4):1071-8.
8382702	Kirkness EF, Fraser CM: A strong promoter element is located between alternative exons of a gene encoding the human gamma-aminobutyric acid-type A receptor beta 3 subunit (GABRB3). J Biol Chem. 1993 Feb 25;268(6):4420-8.

# Drug_Target_1_HGNC_ID:
HGNC:4083

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
4099

# Drug_Target_1_Locus:
15q11.2-q12

# Drug_Target_1_Molecular_Weight:
54116

# Drug_Target_1_Name:
Gamma-aminobutyric-acid receptor subunit beta-3

# Drug_Target_1_Number_of_Residues:
473

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF02931	Neur_chan_LBD
PF02932	Neur_chan_memb

# Drug_Target_1_Protein_Sequence:
>Gamma-aminobutyric-acid receptor subunit beta-3
MWGLAGGRLFGIFSAPVLVAVVCCAQSVNDPGNMSFVKETVDKLLKGYDIRLRPDFGGPP
VCVGMNIDIASIDMVSEVNMDYTLTMYFQQYWRDKRLAYSGIPLNLTLDNRVADQLWVPD
TYFLNDKKSFVHGVTVKNRMIRLHPDGTVLYGLRITTTAACMMDLRRYPLDEQNCTLEIE
SYGYTTDDIEFYWRGGDKAVTGVERIELPQFSIVEHRLVSRNVVFATGAYPRLSLSFRLK
RNIGYFILQTYMPSILITILSWVSFWINYDASAARVALGITTVLTMTTINTHLRETLPKI
PYVKAIDMYLMGCFVFVFLALLEYAFVNYIFFGRGPQRQKKLAEKTAKAKNDRSKSESNR
VDAHGNILLTSLEVHNEMNEVSGGIGDTRNSAISFDNSGIQYRKQSMPREGHGRFLGDRS
LPHKKTHLRRRSSQLKIKIPDLTDVNAIDRWSRIVFPFTFSLFNLVYWLYYVN

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-25

# Drug_Target_1_Specific_Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel

# Drug_Target_1_SwissProt_ID:
P28472

# Drug_Target_1_SwissProt_Name:
GBRB3_HUMAN

# Drug_Target_1_Synonyms:
GABA(A
Gamma-aminobutyric-acid receptor subunit beta-3 precursor

# Drug_Target_1_Theoretical_pI:
9.41

# Drug_Target_1_Transmembrane_Regions:
246-267
271-293
305-327
451-472

#END_DRUGCARD DB00592
